Bristol Myers Squibb Company BMY
62.86
1.36
2.21%
as of 25 Sep
- Market cap
- $125.9B
- P/E
- 13.8×
Follow BMY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bristol Myers Squibb Company (BMY) Total debt
Bristol Myers Squibb Company's total debt at the end of fiscal 2025 was $45.1B, down 9.14% from $49.6B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $43.1B. Over the past ten years it has ranged from $6.7B (fiscal 2015) to $50.7B (fiscal 2020); the current reading is higher than 73% of that period. Bristol Myers Squibb Company ranks 7th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $45.1B | (9.14%) |
| FY2024 | $49.6B | 24.83% |
| FY2023 | $39.8B | 1.15% |
| FY2022 | $39.3B | (11.75%) |
| FY2021 | $44.6B | (12.08%) |
| FY2020 | $50.7B | 8.44% |
| FY2019 | $46.7B | 535.91% |
| FY2018 | $7.3B | (7.70%) |
| FY2017 | $8.0B | 18.69% |
| FY2016 | $6.7B | 0.28% |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $43.1B | (3.01%) |
| Mar 2026 | $44.5B | (1.44%) |
| Dec 2025 | $45.1B | (7.90%) |
| Sep 2025 | $49.0B | (0.42%) |
| 42 more quarters | Free account |
Against its own ten years
Low $6.7B
High $50.7B
Ten-year median
$39.8B
Current reading's percentile
73
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $63.2B |
| AMGN Amgen Inc. compare | $57.3B |
| NVS Novartis AG compare | $47.1B |
| BMY Bristol Myers Squibb Company | $43.1B |
| AZN AstraZeneca PLC compare | $29.5B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| SNY Sanofi compare | $25.2B |
| GSK GSK PLC Sponsored ADR compare | $24.5B |
| NVO Novo Nordisk A/S compare | $21.8B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BMY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement